PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES
First Claim
Patent Images
1. A conjugate of formula:
-
[DRUG]-(A0)nn;
wherein;
DRUG is a compound of formula 518;
wherein;
nn is 1, 2, or 3;
A0 is A1, A or W3 with the proviso that the conjugate includes at least one A1;
A1 is;
A2 is;
A3 is;
Y1 is independently O, S, N(Rx), N(O)(Rx), N(ORx), N(O)(ORx), or N(N(Rx)(Rx));
Y2 is independently a bond, O, N(Rx), N(O)(Rx), N(ORx), N(O)(ORx), N(N(Rx)(Rx)), —
S(O)M2—
, or —
S(O)M2—
S(O)M2—
; and
when Y2 joins two phosphorous atoms Y2 can also be C(R2)(R2);
Rx is independently H, R1, R2, W3, a protecting group, or the formula;
wherein;
R1 is independently H, W3, R2 or a protecting group;
R1 is independently H or alkyl of 1 to 18 carbon atoms;
R2 is independently H, R1, R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups;
R3 is R3a, R3b, R3c or R3d, provided that when R3 is bound to a heteroatom, then R3 is R3c or R3d;
R3a is F, Cl, Br, I, —
CN, N3 or —
NO2;
R3b is Y1;
R3c is Rx, —
N(Rx)(Rx), —
SRx, —
S(O)Rx, —
S(O)2Rx, —
S(O)(ORx), —
S(O)2(ORx), —
OC(Y1)Rx, —
OC(Y1)ORx, —
OC(Y1)(N(Rx)(Rx)), —
SC(Y1)Rx, —
SC(Y1)ORx, —
SC(Y1)(N(Rx)(Rx)), —
N(Rx)C(Y1)Rx, —
N(Rx)C(Y1)ORx, or —
N(Rx)C(Y1)(N(Rx)(Rx));
R3 is —
C(Y1)Rx, —
C(Y1)ORx or —
C(Y1)(N(Rx)(Rx));
R4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;
R5 is R4 wherein each R4 is substituted with 0 to 3 R3 groups;
W3 is W4 or W5;
W4 is R5, —
C(Y1)R5, —
C(Y1)W5, —
SOM2R5, or —
SOM2W5;
W5 is carbocycle wherein W5 is independently substituted with 0 to 3 R2 groups;
W6 is W3 independently substituted with 1, 2, or 3 A3 groups;
M2 is 0, 1 or 2;
M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
M1a, M1c, and M1d are independently 0 or 1; and
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
or a pharmaceutically acceptable salt or solvate thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention is related to phosphorus substituted compounds with activity for treating metabolic diseases and/or disorders, e.g., diabetes and hypercholesterolemia, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
-
Citations
11 Claims
-
1. A conjugate of formula:
-
[DRUG]-(A0)nn;wherein; DRUG is a compound of formula 518; wherein; nn is 1, 2, or 3; A0 is A1, A or W3 with the proviso that the conjugate includes at least one A1; A1 is; A2 is; A3 is; Y1 is independently O, S, N(Rx), N(O)(Rx), N(ORx), N(O)(ORx), or N(N(Rx)(Rx)); Y2 is independently a bond, O, N(Rx), N(O)(Rx), N(ORx), N(O)(ORx), N(N(Rx)(Rx)), —
S(O)M2—
, or —
S(O)M2—
S(O)M2—
; and
when Y2 joins two phosphorous atoms Y2 can also be C(R2)(R2);Rx is independently H, R1, R2, W3, a protecting group, or the formula; wherein; R1 is independently H, W3, R2 or a protecting group; R1 is independently H or alkyl of 1 to 18 carbon atoms; R2 is independently H, R1, R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups; R3 is R3a, R3b, R3c or R3d, provided that when R3 is bound to a heteroatom, then R3 is R3c or R3d; R3a is F, Cl, Br, I, —
CN, N3 or —
NO2;R3b is Y1; R3c is Rx, —
N(Rx)(Rx), —
SRx, —
S(O)Rx, —
S(O)2Rx, —
S(O)(ORx), —
S(O)2(ORx), —
OC(Y1)Rx, —
OC(Y1)ORx, —
OC(Y1)(N(Rx)(Rx)), —
SC(Y1)Rx, —
SC(Y1)ORx, —
SC(Y1)(N(Rx)(Rx)), —
N(Rx)C(Y1)Rx, —
N(Rx)C(Y1)ORx, or —
N(Rx)C(Y1)(N(Rx)(Rx));R3 is —
C(Y1)Rx, —
C(Y1)ORx or —
C(Y1)(N(Rx)(Rx));R4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R5 is R4 wherein each R4 is substituted with 0 to 3 R3 groups; W3 is W4 or W5; W4 is R5, —
C(Y1)R5, —
C(Y1)W5, —
SOM2R5, or —
SOM2W5;W5 is carbocycle wherein W5 is independently substituted with 0 to 3 R2 groups; W6 is W3 independently substituted with 1, 2, or 3 A3 groups; M2 is 0, 1 or 2; M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; M1a, M1c, and M1d are independently 0 or 1; and M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; or a pharmaceutically acceptable salt or solvate thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
3. The conjugate of claim 1 wherein each A3 is of the formula:
-
4. The conjugate of claim 1 wherein each A3 is of the formula:
-
wherein Y2b is O or N(Rx).
-
-
5. The conjugate of claim 1 wherein each A3 is of the formula:
-
6. The conjugate of claim 1 wherein each A3 is of the formula:
-
7. The conjugate of claim 1 wherein each A3 is of the formula:
-
wherein Y2b is O or N(Rx).
-
-
8. The conjugate of claim 1 wherein each A3 is of the formula:
-
wherein the phenyl carbocycle is substituted with 0, 1, 2, or 3 R2 groups.
-
-
9. The conjugate of claim 1 wherein each A3 is of the formula:
-
wherein; Y1a is O or S; Y2b is O or N(R2); and Y2c is O, N(Ry) or S.
-
-
10. The conjugate of claim 1 wherein A0 is of the formula:
-
wherein each R is independently alkyl.
-
-
11. A pharmaceutical composition comprising a pharmaceutical excipient and a conjugate as described in claim 1, or a pharmaceutically acceptable salt or solvate thereof.
Specification